Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

2.

Changes in Composition of the Gut Bacterial Microbiome after Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in a Pediatric Heart Transplant Patient.

Flannigan KL, Rajbar T, Moffat A, McKenzie LS, Dicke F, Rioux K, Workentine ML, Louie TJ, Hirota SA, Greenway SC.

Front Cardiovasc Med. 2017 Apr 4;4:17. doi: 10.3389/fcvm.2017.00017. eCollection 2017.

3.

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection.

Dubberke ER, Mullane KM, Gerding DN, Lee CH, Louie TJ, Guthertz H, Jones C.

Open Forum Infect Dis. 2016 Jun 20;3(3):ofw133. eCollection 2016 Sep.

4.

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes.

Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, Gorbach SL.

Can J Infect Dis Med Microbiol. 2016;2016:8048757. doi: 10.1155/2016/8048757. Epub 2016 May 24.

5.

Differences of the Fecal Microflora With Clostridium difficile Therapies.

Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S91-7. doi: 10.1093/cid/civ252.

PMID:
25922407
6.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators.

Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.

PMID:
24799326
7.

Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.

Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, Josephson MA, Gorbach SL.

Am J Nephrol. 2013;38(1):1-11. doi: 10.1159/000351757. Epub 2013 Jun 20. Erratum in: Am J Nephrol. 2013;38(3):266.

PMID:
23796582
8.

A potential new tool for managing Clostridium difficile infection.

Armstrong GD, Pillai DR, Louie TJ, MacDonald JA, Beck PL.

J Infect Dis. 2013 May 15;207(10):1484-6. doi: 10.1093/infdis/jit069. Epub 2013 Feb 18. No abstract available.

PMID:
23420904
9.

Effect of age on treatment outcomes in Clostridium difficile infection.

Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, Shue YK, Gorbach SL.

J Am Geriatr Soc. 2013 Feb;61(2):222-30. doi: 10.1111/jgs.12090. Epub 2013 Feb 4.

PMID:
23379974
10.

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE; Study 003/004 Teams.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S93-103. doi: 10.1093/cid/cis499.

11.

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61. doi: 10.1093/cid/cis462.

12.

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42. doi: 10.1093/cid/cis338.

13.

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

Sears P, Crook DW, Louie TJ, Miller MA, Weiss K.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S116-20. doi: 10.1093/cid/cis337.

14.

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21. No abstract available.

15.

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL.

Clin Infect Dis. 2011 Sep;53(5):440-7. doi: 10.1093/cid/cir404. Erratum in: Clin Infect Dis. 2011 Dec;53(12):1312. Dosage error in article text.

16.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group.

N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.

17.

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.

Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ.

Aliment Pharmacol Ther. 2009 Mar 15;29(6):626-34. doi: 10.1111/j.1365-2036.2008.03924.x. Epub 2008 Dec 19.

18.

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Louie TJ, Emery J, Krulicki W, Byrne B, Mah M.

Antimicrob Agents Chemother. 2009 Jan;53(1):261-3. doi: 10.1128/AAC.01443-07. Epub 2008 Oct 27.

19.

Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI).

Storck AJ, Laupland KB, Read RR, Mah MW, Gill JM, Nevett D, Louie TJ.

BMC Infect Dis. 2006 Oct 11;6:148.

20.

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Jr, Garber G, Chasan-Taber S, Davidson DM; Tolevamer Study Investigator Group.

Clin Infect Dis. 2006 Aug 15;43(4):411-20. Epub 2006 Jul 11.

PMID:
16838228
21.

Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada.

MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, Henwick S.

J Clin Microbiol. 2006 Jun;44(6):2147-52.

22.

Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options.

Louie TJ.

Clin Infect Dis. 2006 Mar 15;42(6):765-7. Epub 2006 Feb 7. No abstract available.

PMID:
16477550
23.
24.

Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains.

Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, Elsayed S, Pitout JD.

J Infect Dis. 2005 Nov 1;192(9):1606-12. Epub 2005 Sep 26.

PMID:
16206075
25.

Understanding influenza vaccination attitudes at a Canadian cancer center.

Mah MW, Hagen NA, Pauling-Shepard K, Hawthorne JS, Mysak M, Lye T, Louie TJ.

Am J Infect Control. 2005 May;33(4):243-50.

PMID:
15877021
26.

Clostridium difficile infection in hospitals: risk factors and responses.

Louie TJ, Meddings J.

CMAJ. 2004 Jul 6;171(1):45-6. No abstract available.

27.

Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study.

Laupland KB, Davies HD, Church DL, Louie TJ, Dool JS, Zygun DA, Doig CJ.

Infection. 2004 Apr;32(2):59-64.

PMID:
15057568
28.

Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate.

Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, Doig CJ.

Crit Care Med. 2002 Nov;30(11):2462-7.

PMID:
12441755
29.

Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill.

Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, Doig CJ.

J Crit Care. 2002 Mar;17(1):50-7.

PMID:
12040549
30.

Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7).

Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W, Livermore DM, Palepou MF, Woodford N.

Antimicrob Agents Chemother. 2002 Jan;46(1):255-8.

31.

Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.

Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ.

Clin Infect Dis. 2001 Feb 1;32(3):381-90. Epub 2001 Jan 30.

PMID:
11170945
32.

Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.

Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A.

Infect Control Hosp Epidemiol. 2000 Apr;21(4):264-9.

PMID:
10782589
33.

Comparison of ceftiofur sodium and oxytetracycline for treatment of acute interdigital phlegmon (foot rot) in feedlot cattle.

Morck DW, Olson ME, Louie TJ, Koppe A, Quinn B.

J Am Vet Med Assoc. 1998 Jan 15;212(2):254-7.

PMID:
9448831
35.

Should infection control practitioners do follow-up of staff exposures to patient blood and body fluids?

Hope KM, Henderson E, Ledgerwood D, Hume K, Louie TJ.

Am J Infect Control. 1996 Apr;24(2):57-66.

PMID:
8731027
36.

Impact of free verotoxin testing on epidemiology of diarrhea caused by verotoxin-producing Escherichia coli.

Ramotar K, Henderson E, Szumski R, Louie TJ.

J Clin Microbiol. 1995 May;33(5):1114-20.

37.

Direct detection of verotoxin-producing Escherichia coli in stool samples by PCR.

Ramotar K, Waldhart B, Church D, Szumski R, Louie TJ.

J Clin Microbiol. 1995 Mar;33(3):519-24.

38.

Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment.

Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ.

J Clin Microbiol. 1995 Mar;33(3):513-8.

39.

Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole.

Nicolle LE, Louie TJ, Dubois J, Martel A, Harding GK, Sinave CP.

Antimicrob Agents Chemother. 1994 Jun;38(6):1368-73.

40.
41.

Evaluation of enzyme immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients.

Morhart M, Rennie R, Ziola B, Bow E, Louie TJ.

J Clin Microbiol. 1994 Mar;32(3):766-76.

42.

Prolonged and multipatient use of prefilled disposable oxygen humidifier bottles: safety and cost.

Henderson E, Ledgerwood D, Hope KM, Hume K, Krulicki W, Ford G, Golar S, Sutherland L, Louie TJ.

Infect Control Hosp Epidemiol. 1993 Aug;14(8):463-8.

PMID:
8376736
43.

Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis.

Bow EJ, Pater JL, Louie TJ, Feld R, Mandell L, Robson HG, Chow A, Belch A, Miedzinski L, Paul N, Elliott CR, Willan AR.

Can J Infect Dis. 1992 Sep;3(5):235-9.

44.

Effect of interventions on prescribing of antimicrobials for prophylaxis in obstetric and gynecologic surgery.

Zhanel GG, Gin AS, Przybylo A, Louie TJ, Otten NH.

Am J Hosp Pharm. 1989 Dec;46(12):2493-6.

PMID:
2603884
45.

Handwashing practices in an intensive care unit: the effects of an educational program and its relationship to infection rates.

Conly JM, Hill S, Ross J, Lertzman J, Louie TJ.

Am J Infect Control. 1989 Dec;17(6):330-9.

PMID:
2596730
50.

Supplemental Content

Loading ...
Support Center